Earnings Roundup: St. Jude's 1 Bright Spot

St Jude's (STJ) electrophysiology business is the one bright spot in an otherwise dim earnings report.

Apr 17, 2014 at 6:30PM

St. Jude's (NYSE:STJ) tepid first-quarter results mask a quickening in sales for the company's atrial fibrillation products that shouldn't be ignored by investors.

St. Jude has been boosting its atrial fibrillation, or AF, offering in anticipation of doctors embracing procedures like ablation as a first-line option for patients with persistent AF. Those investments are paying off as catheter ablation becomes more common.

Since sales of AF products grew the fastest at St. Jude in the first quarter, let's take a closer look at that business and how it may impact St. Jude in the future.

STJ Chart

STJ data. Source: YCharts.

Big businesses struggle
St. Jude's largest business is cardiac rhythm management, or CRM. That business includes its lineup of implantable defibrillators and pacemakers. During the first quarter, revenue from its CRM business grew just 1% to $687 million. Sales of ICD's grew 2% to $436 million, while sales of pacemakers were flat at a hair above $250 million.

The company's second-largest business, cardiovascular, didn't fare much better.

Total cardiovascular sales, which include vascular and structural heart products, fell 1% to $326 million. Heart product sales were unchanged at $154 million, while vascular sales improved an anemic 1% to $172 million.

Those two businesses, which represent 75% of St. Jude's sales, captured the bulk of investors' attention given their out-sized impact weighed down solid growth in the company's atrial fibrillation business, which grew 8% to $251 million. 

An expanding opportunity
One in four people will suffer from AF -- an irregular heart rhythm -- during their lifetime, making the condition the most common heart related reason for hospital admissions.

Anticoagulant drugs like Johnson & Johnson's (NYSE:JNJ) Xarelto and warfarin are commonly used as part of first-line treatment for AF. However, correcting faulty electrical circuits using catheters to deliver radio frequency energy or refrigerant to damaged heart tissue has been elevated to a first-line treatment option for paroxysmal and persistent AF patients, according to the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation.

The change in those guidelines may boost sales of St. Jude's AF products even more this year, particularly given St. Jude is rolling out TactiCath, a product it acquired when it bought Endosense last year. TactiCath, which measures the force applied by doctors during catheter ablation, is likely to enjoy solid demand given its potential to reduce repeat procedures.

TactiCath won EU approval last year, and St. Jude hopes to win the FDA's blessing later this year. If so, TactiCath's sales could move the profit needle into year-end. During its first-quarter conference call, St. Jude reported that sales of TactiCath in the EU were a major reason behind the company's 13% year-over-year growth in AF sales overseas during the first quarter. For comparison, AF sales grew 5% in the U.S.

Competition heats up
Given the market growth in AF, it's not surprising that St. Jude isn't alone in pursuing the opportunity. The company competes with Boston Scientific (NYSE:BSX), Medtronic (NYSE:MDT), and Johnson & Johnon's Biosense-Webster unit.

Last year, Boston Scientific essentially doubled its electrophysiology market share by acquiring C.R. Bard's EP business for $275 million. That gave Boston Scientific nearly a 10% share of the market, bolstering Boston's struggling EP business, which saw its sales sink 5% in the fourth quarter, ex-acquisitions.

Medtronic has strengthened its market position through a series of acquisitions, including deals to buy Ablation Frontiers, LLC, and CryoCath LP. As a result, Medtronic reported that its AF sales jumped more than 20% in its fiscal third quarter, which ended in January, thanks to sales of its Arctic Front cryoablation system growing over 30%.

And Johnson & Johnson's Biosense Webster is also a big player in AF. For example, Johnson's Carto 3 mapping device, which helps visualize and navigate ablation catheters, is the most widely deployed mapping system in the field. Thanks to 15% growth at Biosense Webster, Johnson reported that its cardiovascular device sales grew 7% to $540 million in the first quarter. 

Foolworthy final thoughts
AF is a serious condition affecting more than 2.5 million people in the U.S. every year. As a result, the global AF market is expected to climb over 13% a year to $14.8 billion by 2019.  Since AF occurs more frequently in older people, the CDC estimates a longer living population will drive the number of Americans with AF to as many as 12 million annually by 2050. 

Those projections have St. Jude estimating that sales of EP products for the AF market will grow in the high-single to low double digits for the "foreseeable future." Given that prediction, investors can expect AF to remain a significant driver behind the company's growth over the coming years.

Six stock picks poised for incredible growth
They said it couldn't be done. But David Gardner has proved them wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.


Todd Campbell has no position in any stocks mentioned. He owns E.B. Capital Markets, LLC, whose clients may or may not have positions in the companies mentioned. He also owns Gundalow Advisors, LLC, whose clients do not have positions in the companies mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. It also owns shares of Medtronic. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

1 Key Step to Get Rich

Our mission at The Motley Fool is to help the world invest better. Whether that’s helping people overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we can help.

Feb 1, 2016 at 4:54PM

To be perfectly clear, this is not a get-rich action that my Foolish colleagues and I came up with. But we wouldn't argue with the approach.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich" rated The Motley Fool as the #1 place online to get smarter about investing.

"The Motley Fool aims to build a strong investment community, which it does by providing a variety of resources: the website, books, a newspaper column, a radio [show], and [newsletters]," wrote (the clearly insightful and talented) money reporter Kathleen Elkins. "This site has something for every type of investor, from basic lessons for beginners to investing commentary on mutual funds, stock sectors, and value for the more advanced."

Our mission at The Motley Fool is to help the world invest better, so it's nice to receive that kind of recognition. It lets us know we're doing our job.

Whether that's helping the entirely uninitiated overcome their fear of stocks all the way to offering clear and successful guidance on complicated-sounding options trades, we want to provide our readers with a boost to the next step on their journey to financial independence.

Articles and beyond

As Business Insider wrote, there are a number of resources available from the Fool for investors of all levels and styles.

In addition to the dozens of free articles we publish every day on our website, I want to highlight two must-see spots in your tour of fool.com.

For the beginning investor

Investing can seem like a Big Deal to those who have yet to buy their first stock. Many investment professionals try to infuse the conversation with jargon in order to deter individual investors from tackling it on their own (and to justify their often sky-high fees).

But the individual investor can beat the market. The real secret to investing is that it doesn't take tons of money, endless hours, or super-secret formulas that only experts possess.

That's why we created a best-selling guide that walks investors-to-be through everything they need to know to get started. And because we're so dedicated to our mission, we've made that available for free.

If you're just starting out (or want to help out someone who is), go to www.fool.com/beginners, drop in your email address, and you'll be able to instantly access the quick-read guide ... for free.

For the listener

Whether it's on the stationary exercise bike or during my daily commute, I spend a lot of time going nowhere. But I've found a way to make that time benefit me.

The Motley Fool offers five podcasts that I refer to as "binge-worthy financial information."

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. It's also featured on several dozen radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable ... and I don't say that simply because the hosts all sit within a Nerf-gun shot of my desk. Rule Breaker Investing and Answers contain timeless advice, so you might want to go back to the beginning with those. The other three take their cues from the market, so you'll want to listen to the most recent first. All are available at www.fool.com/podcasts.

But wait, there's more

The book and the podcasts – both free ... both awesome – also come with an ongoing benefit. If you download the book, or if you enter your email address in the magical box at the podcasts page, you'll get ongoing market coverage sent straight to your inbox.

Investor Insights is valuable and enjoyable coverage of everything from macroeconomic events to investing strategies to our analyst's travels around the world to find the next big thing. Also free.

Get the book. Listen to a podcast. Sign up for Investor Insights. I'm not saying that any of those things will make you rich ... but Business Insider seems to think so.

Compare Brokers